STREPTOSIL ® Sulfatiazole + Neomycin

STREPTOSIL ® is a drug based on Sulfatiazole + Neomycin

THERAPEUTIC GROUP: Antibiotics and chemotherapeutic drugs in combination

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications STREPTOSIL ® Sulfatiazole + Neomycin

STREPTOSIL ® is indicated in the treatment of superficial skin infections caused by microorganisms sensitive to neomycin.

Mechanism of action STREPTOSIL ® Sulfathiazole + Neomycin

STREPTOSIL ® is a particularly effective medicine in the treatment of bacterial infections of the superficial skin thanks to the presence of two active ingredients, both known for their microbicidal properties, which are however distinguished by different and complementary mechanisms of action.

More precisely, neomycin is an antibiotic belonging to the category of aminoglycosides capable of carrying out its therapeutic activity by permeating the bacterial wall and inhibiting the 30S ribosomal subunit, necessary to guarantee the tRNA attack and the related lengthening of the peptide chain.

The resulting production of aberrant peptides, as well as compromising normal cellular activity, damages cell membranes, resulting in massive leakage of potassium, thus facilitating the lysis of the microorganism.

The second active ingredient is sulfatiazole, a synthetic drug belonging to the sulfonamide family, able to compete with the para-aminobenzoioc acid substrate of the enzyme dihydropteroate synthetase, involved in the synthesis of tetrahydrofolic acid.

This last molecule is essential for the synthesis of nucleic acids, so as to significantly prevent bacterial proliferation.

In conclusion, therefore, the therapeutic properties of STREPTOSIL ® occur through the inhibition of bacterial protein synthesis and through the inhibition of genomic replication.

Studies carried out and clinical efficacy

1 NEOMYCIN AS A GROWTH FACTOR

Exp Cell Res. 1995 Jul; 219 (1): 266-75.

Experimental work that demonstrates that probably in addition to the characteristic antibiotic activity, neomycin would be effective in treating skin infections also thanks to the ability to stimulate PDGF production and the growth of human fibroblasts.

2 . NEOMYCIN AND CARCINOMA IN BASAL CELLS

Eur J Med Res. 2005 May 20; 10 (5): 202-3.

Very interesting work that describes how the application of neomycin on a basal cell carcinoma has guaranteed a regression of the lesion, probably controlling the proliferation of endothelial cells and the related neoangiogenesis.

3. NEOMYCIN DERMATITIS

Dermatitis. 2008 Nov-Dec; 19 (6): E46-8.

Interesting case report that reports the worsening of dermatitis in a patient undergoing previous chemotherapy, following the application of useful patches to verify the possible sensitivity to neomycin.

Method of use and dosage

STREPTOSIL ®

Ointment for dermal use from 0.4 g of sulfathiazole and 0.1 g of neomycin sulfate for 20 g of product;

9.95 gr dermal dust of sulfathiazole and 0.05 gr of neomycin sulfate.

For the treatment of superficial bacterial skin infections it is recommended to apply a thin layer of ointment on the area directly affected 2-3 times a day.

Following the application of STREPTOSIL ® in skin powder it would instead be essential to immediately apply a sterile gauze in order to avoid possible dispersion of the drug.

Also in this case the recommended dosage is 2-3 applications per day.

Warnings STREPTOSIL ® Sulfatiazole + Neomycin

For the use of STREPTOSIL ® to be safe, avoiding the appearance of possible side effects related to the systemic absorption of its active ingredients would be necessary:

Avoid applying the drug near mucous and conjunctiva;
Avoid applying the drug on particularly large and compromised regions;
Avoid applying the drug on ulcerated or damaged skin;
Avoid using the occlusive bandage technique.

Prolonged and inadequate use of the product could facilitate the formation of strains resistant to common antibiotic therapy, aggravating the patient's clinical picture.

PREGNANCY AND BREASTFEEDING

Despite the low systemic absorption of the active ingredients minimize the risks associated with taking the drug, the use of STREPTOSIL ® in pregnancy should only take place in cases of real need and under the strict supervision of your doctor.

Interactions

The low systemic absorption of sulfatiazole and neomycin linked to the topical application of these active ingredients, allows to minimize the possible drug interactions capable of compromising the normal therapeutic properties of the drug and its relative safety degree.

Contraindications STREPTOSIL ® Sulfatiazole + Neomycin

The use of STREPTOSIL ® is contraindicated in case of hypersensitivity to the active ingredient and its excipients.

Also remember to avoid contact of the drug with the mucous membranes and conjunctiva.

Undesirable effects - Side effects

Topical use of STREPTOSIL ® avoids the systemic absorption of its active ingredients, thus considerably limiting the appearance of possible systemic side effects.

However, with certain frequency local adverse reactions may occur due to hypersensitivity to the drug, characterized by redness, swelling and persistent itching.